BMO Capital Upgrades Intellia Therapeutics (NTLA) to Outperform, 'Risk/Reward Is Now Skewed to the Upside'
Tweet Send to a Friend
(Updated - March 13, 2023 4:06 PM EDT)
BMO Capital analyst Kostas Biliouris upgraded Intellia Therapeutics (NASDAQ: NTLA) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
BMO Capital analyst Kostas Biliouris upgraded Intellia Therapeutics (NASDAQ: NTLA) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
